A detailed history of Schonfeld Strategic Advisors LLC transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, Schonfeld Strategic Advisors LLC holds 441,794 shares of AKRO stock, worth $13.1 Million. This represents 0.07% of its overall portfolio holdings.

Number of Shares
441,794
Previous 695,723 36.5%
Holding current value
$13.1 Million
Previous $17.6 Million 41.02%
% of portfolio
0.07%
Previous 0.13%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$18.31 - $24.62 $4.65 Million - $6.25 Million
-253,929 Reduced 36.5%
441,794 $10.4 Million
Q1 2024

May 15, 2024

BUY
$17.76 - $31.18 $9.97 Million - $17.5 Million
561,371 Added 417.84%
695,723 $17.6 Million
Q4 2023

Feb 14, 2024

SELL
$11.38 - $50.33 $883,725 - $3.91 Million
-77,656 Reduced 36.63%
134,352 $3.14 Million
Q3 2023

Nov 14, 2023

BUY
$41.19 - $52.25 $1.52 Million - $1.92 Million
36,808 Added 21.01%
212,008 $10.7 Million
Q2 2023

Aug 14, 2023

BUY
$36.89 - $56.88 $4.26 Million - $6.57 Million
115,522 Added 193.58%
175,200 $8.18 Million
Q1 2023

May 15, 2023

SELL
$37.27 - $50.24 $1.43 Million - $1.93 Million
-38,478 Reduced 39.2%
59,678 $2.28 Million
Q4 2022

Feb 14, 2023

BUY
$33.44 - $54.8 $2.98 Million - $4.89 Million
89,256 Added 1002.88%
98,156 $5.38 Million
Q3 2022

Nov 14, 2022

SELL
$10.15 - $34.05 $152,250 - $510,749
-15,000 Reduced 62.76%
8,900 $303,000
Q2 2022

Aug 15, 2022

BUY
$8.0 - $15.01 $116,000 - $217,645
14,500 Added 154.26%
23,900 $225,000
Q2 2021

Aug 16, 2021

BUY
$24.81 - $32.35 $233,214 - $304,090
9,400 New
9,400 $234,000

Others Institutions Holding AKRO

About Akero Therapeutics, Inc.


  • Ticker AKRO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,417,600
  • Market Cap $1.38B
  • Description
  • Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...
More about AKRO
Track This Portfolio

Track Schonfeld Strategic Advisors LLC Portfolio

Follow Schonfeld Strategic Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Schonfeld Strategic Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Schonfeld Strategic Advisors LLC with notifications on news.